SCHEMBL7601614

SCHEMBL7601614

Cc1ccc(-c2c3ccccc3c(-c3ccc(-n4c5ccccc5c5ccccc54)cc3)c3ccccc23)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 2/20 0.43
ATM Q13315 1/20 0.43
TP53 P04637 2/20 0.36
MAPT P10636 3/20 0.36
ALDH1A1 P00352 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KMT2A Q03164 2/20 0.35
HDAC4 P56524 1/20 0.34
EDNRA P25101 2/20 0.33
MAPK14 Q16539 1/20 0.33
NQO2 P16083 1/20 0.33
EDNRB P24530 1/20 0.33
NISCH Q9Y2I1 1/20 0.33
AKR1C4 P17516 1/20 0.32
AKR1C3 P42330 1/20 0.32
AKR1C2 P52895 1/20 0.32
AKR1C1 Q04828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7602374 0.87 L3MBTL1 (0.47) L3MBTL1KDM4EATMTP53MAPT
SCHEMBL7605415 0.82 KDM4E (0.46) L3MBTL1KDM4EATMALDH1A1KMT2A
SCHEMBL7605669 0.82 ATM (0.40) L3MBTL1KDM4EATMMAPK14NPSR1
SCHEMBL275300 0.81 L3MBTL1 (0.64) L3MBTL1KDM4EATMMAPTALDH1A1
SCHEMBL13957181 0.81 KDM4E (0.47) L3MBTL1KDM4EATMMAPTALDH1A1
SCHEMBL9890863 0.80 L3MBTL1 (0.53) L3MBTL1KDM4EATMMAPTALDH1A1
SCHEMBL7601612 0.80 KDM4E (0.53) L3MBTL1KDM4EATMMAPTALDH1A1
SCHEMBL12571778 0.80 L3MBTL1 (0.53) L3MBTL1KDM4EATMMAPTALDH1A1
SCHEMBL7605400 0.80 KDM4E (0.53) L3MBTL1KDM4EATMALDH1A1SMN1; SMN2
SCHEMBL7601620 0.80 CYP11B1 (0.45) L3MBTL1KDM4EATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183793-B2 Method for synthesizing anthracene derivative and anthracene derivative, light emitting element, light emitting device, electronic device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-05-22 US disclosed
US-8183793-B2 Method for synthesizing anthracene derivative and anthracene derivative, light emitting element, light emitting device, electronic device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-05-22 US disclosed
US-20110050118-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-03-03 US disclosed
US-20110050118-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-03-03 US disclosed
US-20080107918-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-05-08 US disclosed
US-20080107918-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-05-08 US disclosed
WO-2008026614-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110050118-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE ALAD, CYP2C9, CYP1A1 L3MBTL1 3456/4885KDM4E 2175/4885ATM 527/4885
US-20080107918-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE ALAD, CYP2C9, CYP1A1 L3MBTL1 3456/4885KDM4E 2175/4885ATM 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.